Novartis Investigative Site

Lubbock, Texas 79430

0 studies enrolling now · 8 studies all time

What they study most

Attention Deficit Hyperactivity Disorder, Carcinoma, Renal Cell, Kidney Transplant, Purpura, Thrombocytopaenic, Idiopathic, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Scelrosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Studies at this site

• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma — Completed
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• EXTEND (Eltrombopag Extended Dosing Study) — Completed
• Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed